Visceral leishmaniasis and hemophagocytic lymphohistiocytosis in a splenectomized patient
DOI:
https://doi.org/10.32818/reccmi.a7n3a10Keywords:
leishmania, lymphohistiocytosis hemophagocytic, pancytopenia, hyperferritinemia, hyperglobulinemiaAbstract
Leishmaniasis is a complex disease caused by at least 20 different species of intracellular parasitic protozoa of the genus Leishmania that causes a variety of syndromes with three clinical forms: cutaneous, mucosal, and visceral. The protozoan preferentially localizes in the mononuclear phagocytic system, and the visceral disease is characterized by a chronic febrile illness with progressive splenomegaly, and hypergammaglobulinemia. We present the case of a 76-year-old female patient, splenectomized more than 20 years ago due to a history of immune thrombocytopenic purpura, admitted to the Internal Medicine Service due to prolonged fever with laboratory findings of hyperferritinemia, and pancytopenia with suspected of hemophagocytic lymphohistiocytosis. Confirmation diagnosis is obtained by bone marrow aspiration, and after starting treatment with amphotericin B, complete resolution of the condition occurs.
Downloads
Metrics
References
Nicolas G, Koury E, Osman D, Saliba C, Nehme L, Mitri S et al. Leishmania in a Patient with Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. Am J Case Rep. 2018; 19: 512-516. doi: https://doi.org/10.12659/AJCR.907584 DOI: https://doi.org/10.12659/AJCR.907584
García Pérez J, Recio Iglesias J, Olivé Gadea M. Visceral leishmania-associated hemophagocytic lymphohistiocytosis. Linfohistiocitosis hemofagocítica secundaria a leishmaniasis visceral. Med Clin (Barc). 2018; 151(5): e25-e26. doi: https://doi.org/10.1016/j.medcli.2018.03.007 DOI: https://doi.org/10.1016/j.medcli.2018.03.007
Jeronimo SMB, de Queiroz Sousa A, Pearson RD. Leishmaniasis. In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant RL, Walker DH, Weller PF (Eds), Saunders Elsevier, Philadelphia 2011. p.696. DOI: https://doi.org/10.1016/B978-0-7020-3935-5.00100-2
Diamantidis MD, Palioura A, Ioannou M, Tsangalas E, Karakousis K Sr. Hemophagocytic Lymphohistiocytosis as a Manifestation of Underlying Visceral Leishmaniasis. Cureus. 2020; 12(12): e11911. doi: https://doi.org/10.7759/cureus.11911 DOI: https://doi.org/10.7759/cureus.11911
Daher EF, Lima LL, Vieira AP, Nascimento LS, Soares DS, Abreu KL et al. Hemophagocytic Syndrome in Children with Visceral Leishmaniasis. Pediatr Infect Dis J. 2015; 34(12): 1311-4. doi: https://doi.org/10.1097/INF.0000000000000916 DOI: https://doi.org/10.1097/INF.0000000000000916
Hemophagocytic Lymphohistiocytosis Study Group. Treatment Protocol of the Second International HLH Study 2004. Histocyte Society. January 2004. Accesible en: https://www.skion.nl/workspace/uploads/HLH-2004-protocol1.pdf (último acceso oct. 2022).
Rajagopala S, Dutta U, Chandra KS, Bhatia P, Varma N, Kochhar R. Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis--case report and systematic review. J Infect. 2008; 56(5): 381-8. doi: https://doi.org/10.1016/j.jinf.2008.02.013 DOI: https://doi.org/10.1016/j.jinf.2008.02.013
Alkhaldy HY, Badri R, Eldeen Bakheet OS. Visceral leishmaniasis with hemophagocytic lymphohistiocytosis (HLH). IDCases. 2020; 21: e00804. doi: https://doi.org/10.1016/j.idcr.2020.e00804 DOI: https://doi.org/10.1016/j.idcr.2020.e00804
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Andrea Afonso-Díaz, María Teresa Busnego-Barreto, César Díaz-Camacho, Guillermo Castro-Gainett, Ana Castellano-Higuera
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
